Table 4 Plasma fatty acid composition in all subjects (A) and in the subgroup not prescribed EPA (B)
SUP | CTR | |||
|---|---|---|---|---|
Variable | 0 week | 16 weeks | 0 week | 16 weeks |
A. All subjects | ||||
EPA (μg/mL) | 62.5 ± 37.0 | 85.8 ± 50.0*, *** | 87.7 ± 76.9 | 87.0 ± 77.2 |
DHA (μg/mL) | 124.1 ± 63.8 | 149.9 ± 95.6 | 116.7 ± 52.9 | 118.4 ± 39.0 |
ARA (μg/mL) | 142.6 ± 45.5 | 142.0 ± 47.3 | 150.7 ± 57.8 | 149.4 ± 44.0 |
α-Linolenic acid (μg/mL) | 33.3 ± 17.2 | 39.0 ± 16.9* | 31.6 ± 23.4 | 29.2 ± 12.9 |
n-3/n-6 ratio | 0.24 ± 0.09 | 0.30 ± 0.11*, *** | 0.28 ± 0.17 | 0.26 ± 0.12 |
EPA/AA ratio | 0.47 ± 0.34 | 0.67 ± 0.51*, *** | 0.72 ± 0.81 | 0.65 ± 0.62 |
B. Subgroup not prescribed EPA | ||||
EPA (μg/mL) | 55.4 ± 34.4 | 75.6 ± 47.7*, *** | 48.4 ± 27.3 | 43.7 ± 21.9 |
EPA/AA ratio | 0.36 ± 0.19 | 0.51 ± 0.26*, *** | 0.31 ± 0.19 | 0.31 ± 0.20 |